iberdomide hydrochloride · Bristol Myers Squibb · NDA 221075
Zenbexus
Earliest generic entry, as listed · earliest of 2 marketed strengths
30 Sep 2039
Blocked by patent: US 11529339. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 7 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11529339 | use U-4598 | 30 Sep 2039 |
| US RE49647 | product | 7 Oct 2034 |
| US RE50917 | use U-4598 | 7 Oct 2034 |
| US 9221788 | substance | 25 Sep 2033 |
| US 9629849 | use U-4598 | 8 Aug 2033 |
| US 8518972 | substance, product | 5 Jun 2031 |
| US 9828361 | substance, product | 10 Feb 2031 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 13 Aug 2031 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 221075 · 001 · RLD | capsule, oral | EQ 0.75MG BASE | 30 Sep 2039 |
| 221075 · 002 · RLD | capsule, oral | EQ 1MG BASE | 30 Sep 2039 |